zintick

ImmunityBio IBRX

ImmunityBio, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$6.67-1.11%close on Nov. 11, 2026 · volume 11.9M · Yahoo Finance

Price, last 57 sessions

$7.00$8.00$9.00$10.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 11, 2026 · high $10.51 · low $6.67 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 5, 2026Barry J. Simon
director
Sold
10b5-1 plan
25,000$10.75$268,760
Oct. 2, 2026Cheryl Cohen
director
Sold
10b5-1 plan
81,056$10.50$851,088

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 10 →
  • 10-QNov. 9, 2026, 7:52 a.m. ETView on SEC.gov
  • 8-KNov. 9, 2026, 7:39 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedImmunityBio Q3 2026 Net Product Revenue of $48.7 Million Up 53% Year-Over-Year, Below $59.2 Million Consensus; Adjusted Loss of $0.09 Per Share vs $0.05 Expected

  • 8-KNov. 9, 2026, 6:33 a.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedImmunityBio Says ANKTIVA Plus BCG Met Primary Endpoint in BCG-Naïve NMIBC Phase QUILT-2.005 Trial; sBLA Planned by Year-End 2026

  • 8-KOct. 14, 2026, 5:19 p.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

  • 4Oct. 6, 2026, 6:06 p.m. ETView on SEC.gov
  • 4Oct. 6, 2026, 6:05 p.m. ETView on SEC.gov
  • SCHEDULE 13D/AAug. 6, 2026, 6:50 p.m. ETView on SEC.gov
  • 10-QAug. 4, 2026, 7:45 a.m. ETView on SEC.gov